VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What’s Driving the Move

Benzinga Earnings11-20 14:33

VivoSim Labs Inc. (NASDAQ:VIVS) shares jumped 21.10% to $0.35 after the bell Thursday, following the company’s announcement of a seven-figure agreement with a top-10 global pharmaceutical company.

Before the markets opened on Thursday, VivoSim said the agreement covers liver and intestinal toxicology testing using its NAMkind platform.

NAMkind uses 3D human cell models, known as New Approach Methodologies (NAMs), to test drug candidates for safety before human trials. Work is already underway.

The release does not name the customer.

VivoSim Raises Fiscal 2027 Revenue Outlook After Top-10 Pharma Deal

VivoSim expects to recognize revenue in its fiscal third and fourth quarters, ending Dec. 31 and Mar. 31, respectively. It now expects fiscal 2027 revenue to exceed its July 15 guidance of more than 500% growth.

Keith Murphy, VivoSim’s executive chairman, said, "This agreement on its own is expected to take us past that number."

VivoSim’s Securities and Exchange Commission filing for the quarter ended Sept. 30 showed growth in both toxicology lines.

The company said its NAMkind Liver model predicted drug-induced liver injury with 91% accuracy across 92 compounds. It said animal models typically detect 50% to 65% of true liver toxicants.

Read Also: Keysight (KEYS) Stock Is Trending After Hours: Here's Why

Non-Animal Drug Testing in Focus

In September, the Food and Drug Administration clarified that non-animal methods may be used to test drug safety.

Tony Lialin, VivoSim’s chief commercial officer, said, "A large customer comes in through an evaluation, then a paid program, then its standing workflow. This customer is at the second step, and we have others at the first."

The announcement resonated well on the stock. In the regular session, VIVS closed at $0.29, up 142.92%, according to Benzinga Pro data.

Trading Metrics, Technical Analysis

The San Diego-based pharmaceutical services company has a market capitalization of about $5.91 million. Over the past 52 weeks, its stock has traded as high as $3.40 and as low as $0.12.

VIVS has a Relative Strength Index (RSI) of 74.66.

Over the past 12 months, the small-cap biotech stock has fallen 86.57%.

Benzinga’s Edge Stock Rankings indicate VivoSim Labs stock has a negative price trend across all time frames.

See More: Top Value Stocks

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo Courtesy: janews on Shutterstock.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment